1. Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer
- Author
-
John Ford, Elaine Cha, C. Sabol, Susan A. McCloskey, Michael B. Bernstein, Bobby Daly, Alyse Kassa, Kathleen Lynch, Xiaolin Mabli, Oren Cahlon, Kiri Sandler, Lior Z. Braunstein, Kaitlyn Lapen, Andrew J. Vickers, Atif J. Khan, Erin F. Gillespie, and Amy Tin
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,MEDLINE ,Breast Neoplasms ,Article ,Breast cancer ,Surveys and Questionnaires ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Patient Reported Outcome Measures ,Mastectomy ,Radiation ,Pilot implementation ,business.industry ,Arrhythmias, Cardiac ,Common Terminology Criteria for Adverse Events ,Monitoring system ,medicine.disease ,Acute toxicity ,Radiation therapy ,Oncology ,Emergency medicine ,Toxicity ,Female ,Electronics ,business - Abstract
We aimed to develop and study the implementation of a remote system for toxicity assessment and management of acute side effects of breast radiation using electronic patient-reported outcomes (ePROs).A response-adapted Patient-Reported Outcomes Common Terminology Criteria for Adverse Events-based assessment for breast radiation toxicity was administered weekly during and for 8 weeks after radiation from June 2019 to July 2020. The care team received alerts when "severe" symptoms were reported by patients, who were then contacted. Treatment, clinic, and sociodemographic characteristics were abstracted from patient records. A subsample of patients and care team members was qualitatively interviewed at follow-up.Overall, 5787 assessments were sent to 678 patients, of whom 489 (72%) completed 2607 assessments (45%). Moderate or greater toxicity was reported by 419 responders (86%; 95% CI, 82%-89%). Clinician alerts for severe toxicity were generated for 264 assessments among 139 unique patients, of which 83% occurred posttreatment. The proportion of surveys that prompted an alert was significantly higher after treatment (219 [13%]) than during treatment (45 [5%]) (P.001). Survey completion rates in the posttreatment period were higher among patients undergoing partial breast irradiation than postmastectomy radiation (incidence rate ratio, 0.70; 95% CI, 0.60-0.81) (P.001) despite these patients experiencing less severe toxicity. Interviews (15) found that patients had a positive experience with ePROs, although many thought the primary purpose was for research rather than symptom management.With the majority of toxicity occurring after breast radiation has ended, remote symptom monitoring with ePROs appears to fill a gap in clinical practice, particularly for patients undergoing shorter courses of radiation. It is important to properly onboard patients and explain that the purpose of ePROs is to aid clinical care. Further research is needed to determine whether the costs associated with ePROs can be offset by reducing routine clinic visits and whether this approach is acceptable and appropriate.
- Published
- 2021